THE WOODLANDS, TX, April  29, 2026  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) (&#34;Autonomix&#34; or the &#34;Company&#34;), a medical device company dedicated to advancing precision nerve-targeted treatments, today

AMIX

Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Autonomix Medical's New Data Accepted for Prominent Conference Presentation

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>THE WOODLANDS, TX, April  29, 2026  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) (&amp;#34;Autonomix&amp;#34; or the &amp;#34;Company&amp;#34;), a medical device company dedicated to advancing precision nerve-targeted treatments, today</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Autonomix Medical, Inc. will present its long-term data on RF energy-based ablation for pancreatic cancer pain at Digestive Disease Week 2026. This development is significant as it highlights the company&#039;s innovative approach to treating debilitating pain, potentially attracting attention from investors and healthcare professionals.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Autonomix Medical&#039;s data accepted for presentation at DDW 2026.</li><li>The research addresses pain in pancreatic adenocarcinoma patients.</li><li>Long-term outcomes highlight effectiveness of RF energy-based ablation.</li><li>Presentation supports Autonomix&#039;s validation at prestigious medical conferences.</li><li>New tech could revolutionize nerve-targeted treatments.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Autonomix Medical, Inc. (AMIX)</strong>: Focuses on innovative solutions for nerve-targeted treatments.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news fits under Corporate Developments due to the focus on advancements in medical technology and significant presentations that could influence company valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Acceptance at DDW 2026 could boost investor confidence and stock price.</li><li>Potential partnerships may arise from exposure at the conference.</li><li>Positive feedback from the medical community may lead to increased adoption.</li><li>Key opinion leader endorsements could strengthen market position.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Study on pancreatic adenocarcinoma pain due for presentation on May 2-5, 2026.</li><li>Autonomix focuses on precision nerve-targeted treatments.</li><li>Company&#039;s technology aims to change pain management significantly.</li><li>Current investigational technology is not yet FDA-approved.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in AMIX on strong conference presentation which may enhance market interest.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><b>THE WOODLANDS, TX, April  29, 2026  (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=rBX3Lxwh0JxlstfzmDC6r0qyf_8rJbrDwsUZ5Yju5F6HCsHcQ-jR2iXmhURJe7bvs5OgyusjntazRVM-nlofMQ3ZQqnYFt99YKQLX8kIjUrlgDrbGTpduyCN5kS9au0f3vMpVk9yZEZPWdELo60Wz53yIZgeuTyuN1RHZPzVMHSkxP0iVKydWszBMghOFHfAosnPu0cYyXnnrh7U8mSv2QdA05LfpG4VjOEhYM9jW5cFuNNpnoeWY6AhNrZ_XWtLOwp3bHj-nM7knn1bWKxPzQ==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMIX">AMIX</a>) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled "<i>Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation</i>" has been accepted for presentation at <a href="https://www.globenewswire.com/Tracker?data=W7zXK4v9avy1yzNy6qGlBlp4BEvgUinGfgOfPXB3sB7YUVxLpz0dX0ogb24bj-Wly1YSi9YTaxKQWNP1weiEzR-e0IYaZZ_VN6u3gffxdDatpzfT5cMNtPYK2g7FQw_ATV3B_AjHW8TnwkKAx81x8kTIFZh1CZ_w87bWS7uRADAjzu677nDwQtVCe0ZZo9Ae3nqtV9adBEVArwnAC_-F4vvRBhHOZuSXM63EbR5qfYQhzXvrLBi8jRKBT4z55Nd2Mhtr1ag7aLAXDnW0X0rYK0BUNEXOJF9hVIYxX5Ee9e4KZGAXvnHOzT0YymsTfZJ2UPHYIH2tn3WyKBSakPID3z-VWiZsmwlg7UXDo09y0YXlWKkr6PztaS1jCXlxwSSWAHlcR8oCFkRk6irgh82FoExZZttvG4qw8QoyYiIMuYU7ryuuHtOS9Dl8JnzSstdyMqgVrWyrym09LADmfK-UNQ==" rel="nofollow" target="_blank">Digestive Disease Week 2026 (DDW 2026)</a>, being held May 2–5, 2026, in Chicago, IL and virtually.</p>  <p align="justify">Pancreatic adenocarcinoma is frequently associated with severe, debilitating pain that significantly impacts patient quality of life. The data to be presented highlights long-term outcomes associated with Autonomix's transvascular radiofrequency (RF) energy-based ablation approach, which is designed to target and disrupt nerve signaling pathways responsible for pain transmission.</p>  <p align="justify">"This acceptance at DDW 2026 underscores our strategy of socializing and validating our data at preeminent conferences alongside world-renowned KOLs and clinical leaders," said Dr. Robert Schwartz, Autonomix Co-Founder and Chief Medical Officer. "We are encouraged by the long-term findings and look forward to sharing these insights with the global gastroenterology and surgical community."</p>  <p align="justify">Digestive Disease Week is one of the world's premier gatherings for physicians, researchers, and industry leaders in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference provides a platform for cutting-edge research and advancements that shape the future of digestive healthcare. For more information, please visit the DDW 2026 conference website <a href="https://www.globenewswire.com/Tracker?data=U5dGopGiFs6hGriQnQfE1k6ZEPiPnGNBJwtSufGGmux23fomtSJKapZ0ck6OS7jPcZmlvUVqpDUCu2Euuaqtxb6zaOmrlkehfURYNFbfIMpv5Dkd-qoMw4UqkIHZMHNqqQFNm3XCRCBs0aUVP-nY2AmvDBzIzFnF_DwFY8xG9etpnt98Z5tL0tgPwxpYOa8CuOTL5Mw4t5ASf_vFnfIWLXwwtstDTBeQhI8ZsawgWI129Im9PIe2GNozu6Ktel0lrnnkYyx250s4KXV3UTWAZsgARTqHfI_a91WS6uhtp1wZMXNPEfXY8tv1AsBSNuNxcytQpG_1jFfKBPBjQ-22-4wmDWYrMx4SB66Z5GT6RADSwT_PtnJ8ldNJqQ-LeKTe-jZQBL8Kg8ezKOF99r7IiQ==" rel="nofollow" target="_blank">here</a>.</p>  <p align="justify"><b>About Autonomix Medical, Inc.</b></p>  <p align="justify">Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.</p>  <p align="justify">We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.</p>  <p align="justify">For more information, visit <a href="https://www.globenewswire.com/Tracker?data=-jB3PliNHqzkjxzTuPCk5Ikik1N3KfSDwM_8MNpPp5zBvuwgU6jYsyqN4NL8aqhG96iY81wBvQfwUH6bxFiGfQ==" rel="nofollow" target="_blank">autonomix.com</a> and connect with the Company on <a href="https://www.globenewswire.com/Tracker?data=cuxNPzqQRK19OXu6T5n4T4sw3HjlpgZ76yFao4ZbfzwuNTPegSTccmILaOwEPyxcQEpGseHN0J-Sjfbl7DZayw==" rel="nofollow" target="_blank">X</a>, <a href="https://www.globenewswire.com/Tracker?data=DsC0gcCxl2UEHLcAypiOXZQ7ps0JCYY2Pp24vLUD10ptrqymFcDfg-PPFCgvZb0iU2l4zBmQHsMBKTLhre0pfGHFD2c4XVP5ZeFK_7bH_mL1CGDN9YK33Qu_A-F8jw4L" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=ybPMAmv0Q0a54CrWA0dhdfxJYAQBj__2hmSXjZs3a6BSe1Zq9P2SWEVl3N_qjhqIxmG7n7gKC0nao-oOP4sytHfJFNuxReUhLVD3BSXmxeU=" rel="nofollow" target="_blank">Instagram</a> and <a href="https://www.globenewswire.com/Tracker?data=o_Tf7qLc3nQd2RarFRH-a-EwnCYyNyfybsWotFq25MZ_HEB0co2yD7upIZoBllE9e-ZsoNJOZBdXeqzMM7rvMZPOvJx-6Q7b4HxrA-iF0yb3jGz3dlcwoav2-tWXqvw-" rel="nofollow" target="_blank">Facebook</a>.</p>  <p align="justify"><b>Forward Looking Statements</b></p>  <p align="justify">Some of the statements in this release are "forward-looking statements," which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as "should," "might," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix&#39;s nerve-targeted treatments for pancreatic cancer pain and other conditions.</p>  <p align="justify">Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.</p>  <p align="justify"><b>Investor and Media Contact</b></p>  <p align="justify">JTC Team, LLC<br></br>Jenene Thomas <br></br>908.824.0775 <br></br><a href="https://www.globenewswire.com/Tracker?data=-jB3PliNHqzkjxzTuPCk5ARtczexKgv0KTxlQymA7OGhDVSE3SfLrjBJpHuOr7dtGS6ziDAGb1aaOINclyDd6I1Y4NtpVnsRQqZsj_hbkc8=" rel="nofollow" target="_blank">autonomix@jtcir.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwOTAzOSM3NTcxNzE3IzUwMDExOTk5Mg=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZTUwMzllZDYtZjU1ZC00OTE2LWJlZTAtNTA0YzY5ZjQxNGM5LTUwMDExOTk5Mi0yMDI2LTA0LTI5LWVu/tiny/Autonomix-Medical-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/8b0ba1bc-43b1-4445-b895-712da30f7df8"><img src="https://ml.globenewswire.com/media/8b0ba1bc-43b1-4445-b895-712da30f7df8/small/logo-png.png" border="0" width="150" height="87" alt="Primary Logo"></img></a></p>

Autonomix Medical, Inc. will present its long-term data on RF energy-based ablation for pancreatic cancer pain at Digestive Disease Week 2026. This development is significant as it highlights the company's innovative approach to treating debilitating pain, potentially attracting attention from investors and healthcare professionals.

Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News